Management ChangeAug 10, 2026, 04:03 PM
Erasca Appoints Charles S. Fuchs as President of R&D
AI Summary
Erasca, Inc. announced the appointment of Charles S. Fuchs, M.D., M.P.H., as its new president of research and development. In connection with his appointment, Dr. Fuchs was granted inducement awards consisting of non-qualified stock options to purchase 1,278,520 shares of Erasca common stock. These options will vest over time, with an initial 25% vesting on August 10, 2027, and the remainder vesting monthly thereafter.
Key Highlights
- Erasca appointed Charles S. Fuchs, M.D., M.P.H., as president of research and development.
- Dr. Fuchs was granted non-qualified stock options to purchase 1,278,520 shares of common stock.
- The options vest 25% on August 10, 2027, with the remainder vesting in 36 equal monthly installments.
- The exercise price is the closing price on the grant date, August 10, 2026.
- The inducement awards were granted under the company's 2026 Employment Inducement Incentive Award Plan.
Price Impact
More from ERAS